Nanoengineering strategies for precision regulation of chimeric antigen receptor T-cell-induced cytokine release syndrome.
Chimeric antigen receptor (CAR)-T cell therapy faces a critical clinical hurdle: cytokine release syndrome (CRS). Current CRS management strategies have limited selectivity and may interfere with CAR-T cell antitumor activity, highlighting the need for more targeted and precisely controllable interventions. Nanoenginee...